Corbus Net Receivables from 2010 to 2024
| CRBP Stock | USD 17.64 0.34 1.89% |
Net Receivables | First Reported 2010-12-31 | Previous Quarter 3 M | Current Value 2.2 M | Quarterly Volatility 681 K |
Check Corbus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Corbus Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 651.3 K, Interest Expense of 3.1 M or Selling General Administrative of 13.9 M, as well as many indicators such as Price To Sales Ratio of 93.82, Dividend Yield of 0.0 or Days Sales Outstanding of 191. Corbus financial statements analysis is a perfect complement when working with Corbus Pharmaceuticals Valuation or Volatility modules.
Corbus | Net Receivables |
Latest Corbus Pharmaceuticals' Net Receivables Growth Pattern
Below is the plot of the Net Receivables of Corbus Pharmaceuticals Holding over the last few years. It is Corbus Pharmaceuticals' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Corbus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Receivables | 10 Years Trend |
|
Net Receivables |
| Timeline |
Corbus Net Receivables Regression Statistics
| Arithmetic Mean | 2,015,614 | |
| Geometric Mean | 1,904,568 | |
| Coefficient Of Variation | 33.79 | |
| Mean Deviation | 639,521 | |
| Median | 2,178,061 | |
| Standard Deviation | 681,007 | |
| Sample Variance | 463.8B | |
| Range | 1.6M | |
| R-Value | 0.82 | |
| Mean Square Error | 167.3B | |
| R-Squared | 0.66 | |
| Significance | 0.0002 | |
| Slope | 124,173 | |
| Total Sum of Squares | 6.5T |
Corbus Net Receivables History
About Corbus Pharmaceuticals Financial Statements
Corbus Pharmaceuticals shareholders use historical fundamental indicators, such as Net Receivables, to determine how well the company is positioned to perform in the future. Although Corbus Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Corbus Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Corbus Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Receivables | 3 M | 2.2 M |
Pair Trading with Corbus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corbus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corbus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Corbus Stock
| 0.95 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.64 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.7 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Corbus Stock
| 0.71 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.68 | OPT | Opthea | PairCorr |
| 0.54 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.38 | PHVS | Pharvaris BV | PairCorr |
| 0.37 | ESLAW | Estrella Immunopharma | PairCorr |
The ability to find closely correlated positions to Corbus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corbus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corbus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corbus Pharmaceuticals Holding to buy it.
The correlation of Corbus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corbus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corbus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Corbus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Corbus Stock Analysis
When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.